专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明公开

EP0791076A1 DIAGNOSTIC METHOD AND KIT FOR DETERMINING KELL BLOOD GROUP GENOTYPE 失效
标题翻译： ON的诊断程序和一个检测试剂盒KELL BLUTGRUPPLN-NENOTYPS的测定
公开(公告)号：EP0791076A1
公开(公告)日：1997-08-27
申请号：EP95940686.0
申请日：1995-11-09
申请人： THE NEW YORK BLOOD CENTER, INC.
发明人： LEE, Soohee , REDMAN, Colvin, L.
IPC分类号： C12N15 , C07K14 , C12N5 , C12P21 , C12Q1
CPC分类号： C07K14/705 , C12Q1/683 , C12Q1/6858 , C12Q1/6876 , C12Q2600/156
摘要： The invention provides a diagnostic method of determining Kell genotype by the identification of the molecular basis of a Kell polymorphism. Specifically, the invention provides a method for determining K1/K2 genotype with great accuracy, overcoming problems associated with traditional serological typing methods. The diagnostic method of the invention preferably employs amplification of K1/K2 nucleic acid sequences, and optionally employs differential cleavage of K1-K2-specific nucleic acid sequences by a restriction enzyme. Also provided are nucleic acid oligomers useful as probes or primers for the method of the invention. Furthermore, diagnostic kits for the determination of Kell genotype are provided.

42. 发明公开

EP0572194A1 Removal of antibodies from blood-derived compositions while retaining coagulation factors 失效转让
标题翻译：从血液来源的组合物中除去抗体，以获得凝血因子。
公开(公告)号：EP0572194A1
公开(公告)日：1993-12-01
申请号：EP93303997.6
申请日：1993-05-24
申请人： THE NEW YORK BLOOD CENTER, INC.
发明人： Horowitz, Bernard , Chin, Sing N.
IPC分类号： A61K35/16 , G01N33/86
CPC分类号： A61K35/16 , G01N33/86
摘要： This invention relates to methods of removing undesired antibodies from blood-derived compositions containing both the antibodies and coagulation factors, such that the coagulation factors are substantially retained in the composition. The undesired antibodies may be blood group antibodies. This invention also relates to compositions in which undesired antibodies have been removed and desired coagulation factors are retained. This invention further relates to methods of inactivating virus an removing undesired antibodies from blood-derived compositions containing virus, antibodies and coagulation factors without removing coagulation factors therefrom, and to the resulting compositions.
摘要翻译：本发明涉及一种去除血液来源的组合物含有所述抗体和凝血因子不期望的抗体的方法，凝血因子检查，DASS模具基本上保留在组合物中。不期望的抗体可以是血型抗体。因此，本发明涉及其中不需要的抗体已被删除和所需的凝血因子被保留的创作。本发明还涉及到在除去血液来源的组合物含病毒，抗体和凝血因子不希望的抗体，而不脱离除去凝固因子有灭活病毒的方法，以及得到的组合物。

43. 发明授权

EP2193802B1 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus 有权
标题翻译：中和单克隆抗体对严重急性呼吸综合征相关的冠状病毒
公开(公告)号：EP2193802B1
公开(公告)日：2012-05-09
申请号：EP10151641.7
申请日：2006-02-08
申请人： The New York Blood Center, Inc.
发明人： Jiang, Shibo , He, Yuxian
IPC分类号： A61K39/00 , A61K39/215 , C07K16/10
CPC分类号： C07K16/10 , C07K2317/34 , C07K2317/76
摘要： An isolated neutralising monoclonal antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) wherein the antibody is produced by Hybridoma 30F9 with ATCC Accession No. PTA-6523.

44. 发明公开

EP2193802A3 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus 有权
标题翻译：中和单克隆抗体对严重急性呼吸综合征相关的冠状病毒
公开(公告)号：EP2193802A3
公开(公告)日：2010-09-01
申请号：EP10151641.7
申请日：2006-02-08
申请人： The New York Blood Center, Inc.
发明人： Jiang, Shibo , He, Yuxian
IPC分类号： A61K39/00 , A61K39/215 , C07K16/10
CPC分类号： C07K16/10 , C07K2317/34 , C07K2317/76
摘要： An isolated neutralising monoclonal antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) wherein the antibody is produced by Hybridoma 30F9 with ATCC Accession No. PTA-6523.

45. 发明授权

EP0904075B1 METHOD FOR TREATING VIRAL INFECTIONS 失效
标题翻译：方法对于病毒感染的治疗
公开(公告)号：EP0904075B1
公开(公告)日：2004-10-06
申请号：EP97923598.3
申请日：1997-05-07
申请人： THE NEW YORK BLOOD CENTER, INC. , BAR-ILAN UNIVERSITY
发明人： BEN-HUR, Ehud , MALIK, Zvi
IPC分类号： A61K31/40 , A61K31/195 , C07C229/08 , C07D487/22 , A61K41/00 , A61P17/00 , A61P17/12
CPC分类号： A61K31/197 , A61K31/195 , A61K31/16 , A61K2300/00
摘要： The present invention provides a method for treating a viral infection in a subject. The method comprises administering to the subject an amount of 5-aminolevulinic acid to cause virus-infected cells to accumulate protoporphyrin in amounts such that upon application of a sufficient dose of red light, the virus-infected, protoporphyrin-accumulated cells will be destroyed; and applying a sufficient dose of red light to the virus-infected, protoporphyrin-accumulated cells to destroy the virus-infected, protoporphyrin-accumulated cells.

46. 发明授权

EP0771146B1 FIBRIN(OGEN) DEGRADATION AND CLOT LYSIS BY FIBRINOLYTIC MATRIX METALLOPROTEINASE 失效
标题翻译：纤维蛋白/纤维蛋白原降解和凝块解决方案通过纤维蛋白溶解的基质金属蛋白酶
公开(公告)号：EP0771146B1
公开(公告)日：2003-12-10
申请号：EP96918996.8
申请日：1996-05-17
申请人： THE NEW YORK BLOOD CENTER, INC.
发明人： BINI, Alessandra
IPC分类号： A61K38/48 , A61L33/00 , A61P7/02
CPC分类号： A61K38/4886
摘要： The invention provides a method of causing the degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances) by means of a fibrinolytic metalloproteinase, preferably an endogenous metalloproteinase such as MMP-3. The method of the invention can be performed in vitro to provide diagnostic information characterizing fibrin(ogen) and fibrinolytic physiology. The method can also be performed in vivo as a method of thrombolytic therapy in which a fibrinolytic metalloproteinase is administered to a subject to degrade thrombus in situ. The endogenous fibrinolytic metalloproteinase can be administered in conjunction with other active agents, preferably with agents having thrombolytic activity to improve thrombolytic and fibrinolytic therapy. The invention further provides compositions containing a fibrinolytic metalloproteinase for the performance of fibrinolytic or thrombolytic procedures. Also provided are kits which include a fibrinolytic metalloproteinase for performing fibrinolytic or thrombolytic procedures.

47. 发明公开

EP0967928A1 METHOD AND APPARATUS FOR ALTERING THE OSMOTIC PRESSURE OF CRYOPRESERVED WHITE STEM CELLS 失效
标题翻译：方法和装置改变冻存白干细胞的渗透压
公开(公告)号：EP0967928A1
公开(公告)日：2000-01-05
申请号：EP98911437.6
申请日：1998-03-06
申请人： Thermogenesis Corporation , THE NEW YORK BLOOD CENTER, INC.
发明人： COELHO, Philip, H. , RUBINSTEIN, PabloRockefeller University Housing , STEVENS, Cladd, E.
IPC分类号： A61B19/00 , A61M5/32 , A61M35/00 , B01L3/00 , B01L11/00 , C12M3/00 , C12N5/06 , C12N5/08
CPC分类号： A01N1/0221 , A01N1/02
摘要： A method, apparatus and product formed from cryoprotected white stem cells suitable for transfusion. The osmotic pressure of the white stem cells is reduced by controlled dilution of cryopreservative from the white stem cells.

48. 发明申请

US20110053138A1 Universal multi-variant detection system 失效
标题翻译：通用多变种检测系统
公开(公告)号：US20110053138A1
公开(公告)日：2011-03-03
申请号：US12011603
申请日：2008-01-28
申请人： Linda Andrus , Carmen Nicola Nichols
发明人： Linda Andrus , Carmen Nicola Nichols
IPC分类号： C12Q1/68 , C12Q1/70
CPC分类号： C12Q1/707 , C12Q1/6818 , C12Q1/6858 , C12Q1/701 , C12Q1/702 , C12Q1/703 , C12Q1/706 , C12Q2537/101 , C12Q2525/301 , C12Q2561/113 , C12Q2535/125
摘要： The present invention provides a method to diagnostically detect the variants of a given pathogen, such as HIV, hepatitis C, hepatitis B (HBV), Parvovirus B19, etc., with the use of a single detection probe.
摘要翻译：本发明提供了使用单个检测探针来诊断性检测给定病原体如HIV，丙型肝炎，乙型肝炎（HBV），细小病毒B19等的变体的方法。

49. 发明授权

US5830468A Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase 失效
标题翻译：纤维蛋白（ogen）纤维蛋白溶解基质金属蛋白酶降解
公开(公告)号：US5830468A
公开(公告)日：1998-11-03
申请号：US446887
申请日：1995-05-17
申请人： Alessandra Bini
发明人： Alessandra Bini
IPC分类号： A61L33/00 , A61K38/43 , A61K38/46 , A61K38/48 , A61K38/55 , A61K48/00 , A61P7/02 , A61P9/10 , C07K1/12 , A61M5/00 , B65D51/24 , C12N9/50
CPC分类号： A61K38/4886
摘要： The invention provides a method of causing the degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances) by means of a fibrinolytic metalloproteinase, such as MMP-3. The method of the invention may be performed in vitro to provide diagnostic information characterizing fibrin(ogen) and the fibrinolytic physiology. The method may also be performed in vivo as a method of thrombolytic therapy in which a fibrinolytic metalloproteinase is administered to a subject to degrade thrombus in situ. The invention further provides compositions containing a fibrinolytic metalloproteinase for the performance of fibrinolytic or thrombolytic procedures. Also provided are kits which include a fibrinolytic metalloproteinase for performing fibrinolytic or thrombolytic procedures.
摘要翻译：本发明提供了通过纤维蛋白溶解性金属蛋白酶（例如MMP-3）引起纤维蛋白（原子）（即纤维蛋白，纤维蛋白原和相关物质）降解的方法。本发明的方法可以在体外进行以提供表征纤维蛋白（ogen）和纤维蛋白溶解生理学的诊断信息。该方法还可以在体内作为血栓溶解治疗的方法进行，其中向受试者施用纤维蛋白溶解性金属蛋白酶以原位降解血栓。本发明还提供含有纤维蛋白溶解性金属蛋白酶用于纤维蛋白溶解或血栓溶解过程的组合物。还提供了包括用于进行纤维蛋白溶解或血栓溶解过程的纤维蛋白溶解性金属蛋白酶的试剂盒。

50. 发明授权

US4118478A Vaccine manufacture for active immunization containing hepatitis B surface antigen and associated antigen 失效
标题翻译：含有乙型肝炎表面抗原和相关抗原的主动免疫疫苗生产
公开(公告)号：US4118478A
公开(公告)日：1978-10-03
申请号：US771728
申请日：1977-02-24
申请人： Alfred M. Prince , John Vnek , Robert A. Neurath , Christian Trepo
发明人： Alfred M. Prince , John Vnek , Robert A. Neurath , Christian Trepo
IPC分类号： A61K39/29 , A61K39/00 , A61K39/42 , C07K14/02 , A61K39/12 , C12K7/00
CPC分类号： C07K14/005 , A61K39/00 , C12N2730/10122
摘要： A process for preparing a vaccine containing unprecipitated filaments and hepatitis B Dane particle specific antigens by removal from a blood serum of other proteinaceous matter such that the serum contains less than 10% proteinaceous matter other than that associated with hepatitis B surface antigen or the filament or Dane particle specific antigen. Any virus present is inactivated, and the antigenous mass is diluted with a physiologically acceptable medium.
摘要翻译：一种通过从其他蛋白质物质的血清中除去含有未沉淀的细丝和乙型肝炎Dane颗粒特异性抗原的疫苗的方法，使得血清含有少于10％的蛋白质物质，而不是与乙型肝炎表面抗原或细丝相关的蛋白质物质丹参颗粒特异性抗原。存在的任何病毒被灭活，并且用生理上可接受的培养基稀释抗原质量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式